If you are looking for international dividend exposure, look
at global dividend growth funds to diversify your portfolio.
Not exact matches
All
dividend stocks risk a hit to earnings from interest rates in the short term, says Rich Peterson, a senior director
at S&P
Global Market Intelligence.
«You've been able to find pockets of strength even this year,» says Bruce Cooper, who heads all equity teams
at TD Asset Management and manages a
global dividend fund.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain
global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or
at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay
dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
In the European market, the oil sector has a high
dividend yield of about 6 percent — the highest there is — which adds up to real value, says Nick Nelson, head of
global and European equity strategy
at UBS.
Indeed, there are
at least three situations in which focusing on Canadian
dividend payers may well be superior to a
global indexing strategy:
Dividends4Life presents Kimberly - Clark Co. (KMB)
Dividend Stock Analysis posted
at Dividends Value, saying, «Kimberly Clark Corp. is a
global consumer products company produces tissue, personal care and health care.
Dividends4Life presents Medtronic Inc. (MDT)
Dividend Stock Analysis posted
at Dividends Value, saying, «Medtronic Inc. is a
global medical device manufacturer has leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management and other medical markets.
Seeks to offer exposure to high
dividend yielding
global firms that follow a managed -
dividends policy of having increasing or stable
dividends for
at least ten consecutive years
At the time of
global recession in 2007 - 08, the small cap companies had a higher drawdown in comparison to the large mid cap companies which led to higher
dividend yield of the small cap companies in that period.
For February, my stock buy was 80 shares of Virtus
Global Dividend & Income Fund Inc (NYSE: ZTR)
at $ 11.38 per share.
First, I added 100 shares (
at $ 11.75 each) of Virtus
Global Dividend & Income Fund (NYSE: ZTR) to my dividend investing portfolio for a total of 300 shares
Dividend & Income Fund (NYSE: ZTR) to my
dividend investing portfolio for a total of 300 shares
dividend investing portfolio for a total of 300 shares of ZTR.
(2) Estimated Extraordinary
Dividend payments of $ 55.8 million are associated with 14,886,107 shares of our common stock outstanding as of June 16, 2009 and Extraordinary Dividend payments of $ 1.7 million are associated with 460,828 shares of our common stock subject to currently vested options that are in - the - money at $ 4.13, the per share closing price of our stock on the Nasdaq Global Market on June 16, 2009, which options are assumed to be exercised prior to the dividend
Dividend payments of $ 55.8 million are associated with 14,886,107 shares of our common stock outstanding as of June 16, 2009 and Extraordinary
Dividend payments of $ 1.7 million are associated with 460,828 shares of our common stock subject to currently vested options that are in - the - money at $ 4.13, the per share closing price of our stock on the Nasdaq Global Market on June 16, 2009, which options are assumed to be exercised prior to the dividend
Dividend payments of $ 1.7 million are associated with 460,828 shares of our common stock subject to currently vested options that are in - the - money
at $ 4.13, the per share closing price of our stock on the Nasdaq
Global Market on June 16, 2009, which options are assumed to be exercised prior to the
dividend dividend payment.
(3) Estimated proceeds from the exercise of currently vested options for 460,828 shares of our common stock that are in - the - money
at $ 4.13, the per share closing price of our stock on the Nasdaq
Global Market on June 16, 2009, which options are assumed to be exercised prior to the
dividend payment.
These tax credits can pay enormous
dividends at low cost: by helping reduce tropical deforestation, they'll cut the source of 15 of
global carbon pollution, more than all the cars, trucks, ships, and planes in the world combined.
Note: the author is a 2006 graduate of the Climate and Society Masters Program, but is in no way involved in the conference.: 350 Conference: Climate and Society More on 350 ppm 350: The Most Important Number of Your Lifetime 350 Presidential Election UN Climate Talks Invite Campaign Launches Today 350: Bill McKibben Inspires UK Audience to Join His Campaign Brighter Planet and 350.org Challenge Bloggers to Offset Carbon Emissions with Onsite Badge More on James Hansen Climate Expert James Hansen Supports Cap - and -
Dividend System Dr. James Hansen Calls on Americans to Join Him
at the Largest Protest on
Global Warming in U.S. History Nature and Stop Kingsworth Interview James Hansen about His Clash with Big Coal James Hansen's Declaration of Stewardship For the Earth and All Creation
At a fraction of the cost and time it currently takes to launch a securities token, Polymath - powered issuers will be able to launch custom tokens that can pay
dividends, govern management, conduct proxy votes and collect fees — all while complying with
global KYC / AML requirements via smart contract technology.»